ProfileGDS5678 / 1433529_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 53% 64% 62% 59% 60% 54% 73% 60% 72% 60% 65% 61% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3302853
GSM967853U87-EV human glioblastoma xenograft - Control 23.2852753
GSM967854U87-EV human glioblastoma xenograft - Control 33.8391164
GSM967855U87-EV human glioblastoma xenograft - Control 43.6510662
GSM967856U87-EV human glioblastoma xenograft - Control 53.4994459
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6824460
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4178654
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7347673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5880860
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.621772
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5691460
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8583665
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6524961
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6254361